Contact our responsive and friendly client services team any time.
(03) 9028 2888
clients@freshequities.com
INVESTOR PRESENTATION - Immuron Limited
Health
Immuron Ltd is an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
announcement | t+2 movement | date |
---|---|---|
| -2.22% | 10 Jan 2021 |
| -2.22% | 10 Jan 2021 |
| +2.08% | 14 Dec 2020 |
| -1.96% | 25 Nov 2020 |
| -1.92% | 23 Nov 2020 |
| +4.00% | 18 Nov 2020 |
| +6.00% | 17 Nov 2020 |
| +6.00% | 17 Nov 2020 |
| 0.00% | 15 Nov 2020 |
| -1.96% | 13 Nov 2020 |
Current Price
52WK HIGH
52WK LOW
1YR RETURN
1YR RETURN VS. SECTOR
90 DAY RETURN
ASX RANK
/2,047
SECTOR RANK
/168
SHARES OUTSTANDING
Health
Immuron Ltd is an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
ASX:IMC is not raising right now
Want to invest?
(03) 9028 2888
clients@freshequities.com
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia